BE2018C008I2 - - Google Patents

Download PDF

Info

Publication number
BE2018C008I2
BE2018C008I2 BE2018C008C BE2018C008C BE2018C008I2 BE 2018C008 I2 BE2018C008 I2 BE 2018C008I2 BE 2018C008 C BE2018C008 C BE 2018C008C BE 2018C008 C BE2018C008 C BE 2018C008C BE 2018C008 I2 BE2018C008 I2 BE 2018C008I2
Authority
BE
Belgium
Prior art keywords
represent
alkoxy
present
compounds
solvates
Prior art date
Application number
BE2018C008C
Other languages
English (en)
Dutch (nl)
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18980738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2018C008(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of BE2018C008I2 publication Critical patent/BE2018C008I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polymerization Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BE2018C008C 2001-04-27 2018-02-08 BE2018C008I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001132775 2001-04-27
PCT/JP2002/004279 WO2002088110A1 (fr) 2001-04-27 2002-04-26 Derives de quinoline ayant un groupe azolyle et derives de quinazoline

Publications (1)

Publication Number Publication Date
BE2018C008I2 true BE2018C008I2 (fr) 2021-02-04

Family

ID=18980738

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2018C008C BE2018C008I2 (fr) 2001-04-27 2018-02-08

Country Status (24)

Country Link
US (2) US6821987B2 (fr)
EP (2) EP1382604B1 (fr)
JP (1) JP2010077131A (fr)
KR (1) KR100879669B1 (fr)
CN (1) CN1273466C (fr)
AT (1) ATE396988T1 (fr)
AU (1) AU2002255284B2 (fr)
BE (1) BE2018C008I2 (fr)
BR (1) BRPI0209216B8 (fr)
CA (1) CA2445333C (fr)
DE (2) DE60226912D1 (fr)
DK (1) DK1382604T3 (fr)
ES (1) ES2256466T3 (fr)
FR (1) FR18C1006I2 (fr)
IL (1) IL158459A0 (fr)
MX (1) MXPA03009662A (fr)
NL (1) NL300927I9 (fr)
NO (2) NO326325B1 (fr)
NZ (1) NZ529046A (fr)
PL (1) PL209822B1 (fr)
RU (1) RU2283841C2 (fr)
TW (1) TWI324154B (fr)
WO (1) WO2002088110A1 (fr)
ZA (1) ZA200307861B (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3519368B2 (ja) * 1999-01-22 2004-04-12 麒麟麦酒株式会社 キノリン誘導体およびキナゾリン誘導体
TWI281915B (en) * 1999-12-24 2007-06-01 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
AU2002255284B2 (en) 2001-04-27 2007-10-04 Kyowa Kirin Co., Ltd. Quinoline derivative having azolyl group and quinazoline derivative
EP2088141A3 (fr) * 2001-06-22 2009-11-18 Kirin Pharma Kabushiki Kaisha Dérivés de quinoline et de quinazoline capables d'inhiber l'autophosphorylation des récepteurs du facteur de croissance des hépatocytes et composition pharmaceutique les comprenant
WO2003033472A1 (fr) * 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
WO2003093238A1 (fr) * 2002-05-01 2003-11-13 Kirin Beer Kabushiki Kaisha Derives de quinoleine et derives de quinazoline inhibiteurs de l'autophosphorylation du recepteur du facteur stimulant la proliferation des macrophages
EP2280003B1 (fr) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Procédé pour la préparation de modulateurs de kinases de type récepteur
WO2004035572A1 (fr) * 2002-10-21 2004-04-29 Kirin Beer Kabushiki Kaisha Sel de n-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)uree sous forme cristalline
US20080207617A1 (en) * 2002-10-29 2008-08-28 Kirin Beer Kabushiki Kaisha Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
JPWO2004080462A1 (ja) * 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
EP2392565B1 (fr) 2003-09-26 2014-03-19 Exelixis, Inc. Modulateurs de c-Met et procédés d'utilisation
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
CA2545711A1 (fr) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Derives d'uree en tant que modulateurs de la kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2005073224A2 (fr) * 2004-01-23 2005-08-11 Amgen Inc Composes et methodes d'utilisation de ces derniers
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
CA2603748A1 (fr) * 2005-04-06 2006-10-12 Exelixis, Inc. Modulateurs c-met modulators et procedes d'utilisation
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
WO2007015569A1 (fr) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. Procédé de prédiction de l’efficacité d’un inhibiteur de vascularisation
EP1925676A4 (fr) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Procédé d'analyse de l' effet d 'un inhibiteur de vascularisation
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP1938842A4 (fr) * 2005-09-01 2013-01-09 Eisai R&D Man Co Ltd Procédé de préparation de composition pharmaceutique ayant une meilleure capacite de désintégration
JPWO2007052849A1 (ja) * 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
WO2007061127A1 (fr) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. Agent antitumeur pour myelomes multiples
RU2448708C3 (ru) * 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
EP2044939A1 (fr) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
WO2008093855A1 (fr) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
ES2635131T3 (es) 2007-08-29 2017-10-02 Methylgene Inc. Inhibidores de la actividad de la proteína tirosina cinasa
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
HUE025197T2 (en) * 2008-03-17 2016-02-29 Ambit Biosciences Corp Quinazoline derivatives as RAF kinase modulators and methods for their use
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
TH121482A (th) 2009-08-19 2013-02-28 นางสาวปัณณพัฒน์ เหลืองธาตุทอง องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
US7998973B2 (en) * 2009-11-13 2011-08-16 Aveo Pharmaceuticals, Inc. Tivozanib and temsirolimus in combination
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US20130225581A1 (en) * 2010-07-16 2013-08-29 Kyowa Hakko Kirin Co., Ltd Nitrogen-containing aromatic heterocyclic derivative
EA022873B1 (ru) 2010-10-27 2016-03-31 Новартис Аг Применение ингибитора vegf-r2 для лечения офтальмологического сосудистого заболевания
WO2012144463A1 (fr) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent thérapeutique pour les tumeurs
EP3444363B1 (fr) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
CN102532116B (zh) * 2011-08-09 2015-01-21 武汉迈德森医药科技有限公司 抗肿瘤靶向治疗药物tivozanib的合成方法
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408418A (zh) * 2011-10-21 2012-04-11 武汉迈德森医药科技有限公司 Tivozanib酸性盐及其制备方法和晶型
EP2626073A1 (fr) 2012-02-13 2013-08-14 Harmonic Pharma Composé destiné à être utilisé dans la prévention et/ou le traitement d'une maladie neurodégénérative ou d'une maladie impliquant une activation de phosphodiesterase-4 (PDE4)
RU2015115397A (ru) 2012-12-21 2017-01-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аморфная форма производного хинолина и способ его получения
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
EA201690212A8 (ru) 2013-07-12 2016-08-31 Офтотек Корпорейшн Способы лечения или профилактики офтальмологических патологических состояний
KR20230043234A (ko) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
SG11201705767PA (en) 2015-01-13 2017-08-30 Univ Kyoto Agent for preventing and/or treating amyotrophic lateral sclerosis
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
CA2994925C (fr) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Agent therapeutique pour tumeur
WO2017062500A2 (fr) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activateurs de flux autophagique et de phospholipase d et clairance d'agrégats de protéines comprenant tau et traitement de protéinopathies
CN107698562A (zh) * 2016-08-09 2018-02-16 殷建明 一种喹啉衍生物及其用途
CN106478621B (zh) * 2016-09-30 2018-12-25 遵义医学院 喹啉或喹唑啉类衍生物、制备方法及其应用
JP7105774B2 (ja) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
CN108341813B (zh) * 2017-01-24 2020-11-17 四川大学 取代的1-(异恶唑-3-基)-3-(3-氟-4-苯基)脲衍生物及其制备方法和用途
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CN108530455B (zh) 2017-03-01 2021-01-12 北京赛特明强医药科技有限公司 脲取代的芳环连二噁烷并喹唑啉类化合物或药用盐或水合物及作为酪氨酸激酶抑制剂的应用
WO2018197643A1 (fr) * 2017-04-27 2018-11-01 Astrazeneca Ab Composés de phénoxyquinalzoline et leur utilisation en traitement d'un cancer
EP3615522B1 (fr) 2017-04-27 2021-08-04 Astrazeneca AB Composés de c5-quinazoleine et leur utilisation pour la traitenet de la cancer.
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
CN109553612B (zh) * 2017-09-26 2021-09-03 广西梧州制药（集团）股份有限公司 一种吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途
EP3750894B1 (fr) 2018-02-11 2024-04-03 Beijing Scitech-MQ Pharmaceuticals Limited Composé de dioxazoline lié au cycle aromatique à substitution d'urée, son procédé de préparation et ses applications
CA3118690A1 (fr) 2018-11-05 2020-05-14 Aveo Pharmaceuticals, Inc. Utilisation de tivozanib pour traiter des sujets atteints d'un cancer refractaire
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2023081923A1 (fr) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Inhibiteurs du récepteur du facteur de croissance dérivé des plaquettes (pdgfr) alpha et leurs utilisations
WO2023096651A1 (fr) 2021-11-26 2023-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Méthodes de traitement des cancers du conduit biliaire avec du tivozanib
AU2023274540A1 (en) 2022-05-24 2024-12-12 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2024095127A1 (fr) 2022-10-31 2024-05-10 Pliva Hrvatska D.O.O. Formes à l'état solide de tivozanib et leur procédé de préparation
WO2024110606A1 (fr) 2022-11-25 2024-05-30 Synthon B.V. Procédé de préparation de cabozantinib ou de tivozanib
WO2025120654A1 (fr) * 2023-12-05 2025-06-12 Natco Pharma Limited Procédé amélioré pour préparation d'hydrate de chlorhydrate de tivozanib
WO2025253311A1 (fr) 2024-06-04 2025-12-11 Hetero Labs Limited Composés 1,2-dicarboxamide utilisés en tant qu'inhibiteurs de kinase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2728878B2 (ja) 1987-12-15 1998-03-18 大倉工業株式会社 中空押出成形板
GB9000644D0 (en) * 1990-01-11 1990-03-14 Erba Carlo Spa New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
WO1997017329A1 (fr) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
ES2154253T3 (es) 1997-12-22 2012-01-27 Bayer Healthcare Llc Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas.
EP1047418B1 (fr) * 1997-12-22 2005-07-27 Bayer Pharmaceuticals Corp. Inhibition de raf kinase au moyen d'urees heterocycliques substituees
JP3519368B2 (ja) * 1999-01-22 2004-04-12 麒麟麦酒株式会社 キノリン誘導体およびキナゾリン誘導体
TWI281915B (en) 1999-12-24 2007-06-01 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
JP2002030083A (ja) 2000-07-18 2002-01-29 Kirin Brewery Co Ltd Ｎ−（２−クロロ−４−｛［６−メトキシ−７−（３−ピリジルメトキシ）−４−キノリル］オキシ｝フェニル）−ｎ’−プロピルウレアの二塩酸塩
ATE419239T1 (de) * 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
AU2002255284B2 (en) * 2001-04-27 2007-10-04 Kyowa Kirin Co., Ltd. Quinoline derivative having azolyl group and quinazoline derivative

Also Published As

Publication number Publication date
EP1652847A1 (fr) 2006-05-03
CN1543459A (zh) 2004-11-03
US20030087907A1 (en) 2003-05-08
NZ529046A (en) 2005-10-28
CA2445333A1 (fr) 2002-11-07
IL158459A0 (en) 2004-05-12
CN1273466C (zh) 2006-09-06
DK1382604T3 (da) 2006-04-18
ZA200307861B (en) 2004-10-08
NO326325B1 (no) 2008-11-10
ATE396988T1 (de) 2008-06-15
KR100879669B1 (ko) 2009-01-21
US7211587B2 (en) 2007-05-01
US6821987B2 (en) 2004-11-23
NO20034595L (no) 2003-12-19
NO20034595D0 (no) 2003-10-14
BR0209216A (pt) 2004-07-06
FR18C1006I1 (fr) 2018-03-16
KR20040015143A (ko) 2004-02-18
MXPA03009662A (es) 2004-12-06
NO2018005I1 (no) 2018-02-05
PL367105A1 (en) 2005-02-21
NL300927I1 (nl) 2018-12-04
EP1652847A3 (fr) 2006-08-02
BRPI0209216B8 (pt) 2021-05-25
WO2002088110A1 (fr) 2002-11-07
EP1382604B1 (fr) 2005-12-28
JP2010077131A (ja) 2010-04-08
TWI324154B (fr) 2010-05-01
CA2445333C (fr) 2011-03-22
DE60208364T2 (de) 2006-09-28
FR18C1006I2 (fr) 2019-03-01
DE60208364D1 (de) 2006-02-02
EP1652847B1 (fr) 2008-05-28
RU2283841C2 (ru) 2006-09-20
US20040229876A1 (en) 2004-11-18
DE60226912D1 (de) 2008-07-10
EP1382604A4 (fr) 2004-09-08
BRPI0209216B1 (pt) 2017-05-30
AU2002255284B2 (en) 2007-10-04
ES2256466T3 (es) 2006-07-16
RU2003134376A (ru) 2005-04-20
EP1382604A1 (fr) 2004-01-21
HK1070649A1 (en) 2005-06-24
NL300927I9 (nl) 2019-02-05
PL209822B1 (pl) 2011-10-31

Similar Documents

Publication Publication Date Title
BE2018C008I2 (fr)
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
EA200300982A1 (ru) Гетероциклические производные для лечения рака и других пролиферативных заболеваний
DE69529619D1 (en) Pyrimidinylpyrazolderivate
PT1362854E (pt) Derivados benzo[b]tiofeno e processos para o produzir
FI952420A0 (fi) Glukopyranosidibentsotiofeenit
MXPA03006057A (es) Proceso para preparar (+) trans-4-p-fluorofenil -3 hidroximetil.
EP1251129A4 (fr) Derives de la pyrimidine a effet anti-tumoral
EP1466900A4 (fr) Derives de la vitamine d-double substitution